WallStSmart

Brookfield Asset Management Ltd. (BAM)vsBlackRock Health Sciences Trust II (BMEZ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BAM leads profitability with a 49.7% profit margin vs 0.0%. BMEZ trades at a lower P/E of 5.7x. BAM earns a higher WallStSmart Score of 68/100 (B-).

BAM

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 9.5Value: 5.0Quality: 5.0
Piotroski: 3/9Altman Z: 1.97

BMEZ

Avoid

30

out of 100

Grade: F

Growth: 3.3Profit: 4.0Value: 6.7Quality: 6.0
Piotroski: 3/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BAM5 strengths · Avg: 9.4/10
Return on EquityProfitability
33.0%10/10

Every $100 of equity generates 33 in profit

Profit MarginProfitability
49.7%10/10

Keeps 50 of every $100 in revenue as profit

Operating MarginProfitability
64.5%10/10

Strong operational efficiency at 64.5%

Market CapQuality
$76.25B9/10

Large-cap with strong market position

Revenue GrowthGrowth
23.8%8/10

Revenue surging 23.8% year-over-year

BMEZ2 strengths · Avg: 10.0/10
P/E RatioValuation
5.7x10/10

Attractively priced relative to earnings

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Areas to Watch

BAM4 concerns · Avg: 3.8/10
P/E RatioValuation
30.6x4/10

Premium valuation, high expectations priced in

Price/BookValuation
9.9x4/10

Trading at 9.9x book value

Altman Z-ScoreHealth
1.974/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

BMEZ4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$904.39M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
5.7%3/10

ROE of 5.7% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BAM

The strongest argument for BAM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 49.7% and operating margin at 64.5%. Revenue growth of 23.8% demonstrates continued momentum.

Bull Case : BMEZ

The strongest argument for BMEZ centers on P/E Ratio, Debt/Equity.

Bear Case : BAM

The primary concerns for BAM are P/E Ratio, Price/Book, Altman Z-Score.

Bear Case : BMEZ

The primary concerns for BMEZ are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

BAM profiles as a growth stock while BMEZ is a value play — different risk/reward profiles.

BAM is growing revenue faster at 23.8% — sustainability is the question.

BAM generates stronger free cash flow (339M), providing more financial flexibility.

Monitor ASSET MANAGEMENT industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BAM scores higher overall (68/100 vs 30/100), backed by strong 49.7% margins and 23.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Brookfield Asset Management Ltd.

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

Brookfield Asset Management is a leading global alternative asset manager and one of the largest investors in real assets.

Visit Website →

BlackRock Health Sciences Trust II

FINANCIAL SERVICES · ASSET MANAGEMENT · USA

BlackRock Health Sciences Trust II (BMEZ) is a closed-end fund designed to deliver high total returns by investing in a diversified portfolio focused primarily on the health sciences sector, encompassing pharmaceuticals, biotechnology, and medical devices. Backed by BlackRock's extensive investment management experience, BMEZ seeks to capitalize on substantial growth prospects driven by demographic shifts and increasing healthcare spending. The fund's disciplined and strategic investment approach positions it as a compelling choice for institutional investors looking to enhance their portfolios while navigating the dynamic and innovative landscape of the health sciences industry.

Want to dig deeper into these stocks?